130 related articles for article (PubMed ID: 38130705)
1. Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.
Aldecoa KAT; Macaraeg CSL; Dadlani A; Yadlapalli S
Case Rep Hematol; 2023; 2023():1691996. PubMed ID: 38130705
[TBL] [Abstract][Full Text] [Related]
2. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Zhou Y; Lu H; Yang M; Xu C
Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
[TBL] [Abstract][Full Text] [Related]
4. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
5. A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Ozturk E; Erdogan Ozunal I
Medeni Med J; 2021; 36(2):176-179. PubMed ID: 34239769
[TBL] [Abstract][Full Text] [Related]
6. Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia.
Wang L; Wu S; Yu G; Sui X; Chu X; Liu X
J Oncol Pharm Pract; 2023 Dec; 29(8):2031-2036. PubMed ID: 37518980
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
Deering KL; Sundaram M; Harshaw Q; Trudeau J; Barrientos JC
PLoS One; 2022; 17(10):e0270291. PubMed ID: 36201482
[TBL] [Abstract][Full Text] [Related]
8. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
9. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur V; Swami A
Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
[TBL] [Abstract][Full Text] [Related]
11. A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia.
Skelton WP; Akhavan NN; Taylor ZA; Nguyen TC; Hassan H; Townsend TN; Pathak P; Trikha G; Dang NH; Dang LH; Ali A
Case Rep Oncol Med; 2016; 2016():6980198. PubMed ID: 27999696
[No Abstract] [Full Text] [Related]
12. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
13. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA
Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822
[TBL] [Abstract][Full Text] [Related]
14. Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting for Hyphema.
Păsărică MA; Curcă PF; Dragosloveanu CDM; Tătaru CI; Manole IR; Murgoi GE; Grigorescu AC
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741122
[TBL] [Abstract][Full Text] [Related]
15. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
[TBL] [Abstract][Full Text] [Related]
16. Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
Cheng L; Huang M; Wei J; Xu H; Zhou M; Jiang L
Ann Palliat Med; 2022 May; 11(5):1833-1837. PubMed ID: 34328006
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
18. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
19. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
Wright N; Voshtina E; George G; Singavi A; Field J
Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832
[TBL] [Abstract][Full Text] [Related]
20. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
